Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma

NCT05847569 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05847569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05847569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
January 4, 2024
Completion date
June 29, 2034
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent multiple myeloma, refractory multiple myeloma